“The purpose of this study was the generation of central nervous system (CNS)-excluded cannabinoid receptor agonists to test the hypothesis that inhibition of spasticity, due to CNS autoimmunity, could be controlled by affecting neurotransmission within the periphery…
In summary, CNS-excluded CB1 receptor agonists are a novel class of therapeutic agent for spasticity.”